{"protocolSection":{"identificationModule":{"nctId":"NCT00532779","orgStudyIdInfo":{"id":"NB-301"},"secondaryIdInfos":[{"id":"COR-I","type":"OTHER","domain":"Orexigen Therapeutics, Inc."}],"organization":{"fullName":"Orexigen Therapeutics, Inc","class":"INDUSTRY"},"briefTitle":"A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects"},"statusModule":{"statusVerifiedDate":"2014-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2009-05","type":"ACTUAL"},"completionDateStruct":{"date":"2009-05","type":"ACTUAL"},"studyFirstSubmitDate":"2007-09-19","studyFirstSubmitQcDate":"2007-09-19","studyFirstPostDateStruct":{"date":"2007-09-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-20","resultsFirstSubmitQcDate":"2014-11-18","resultsFirstPostDateStruct":{"date":"2014-11-21","type":"ESTIMATED"},"dispFirstSubmitDate":"2012-10-31","dispFirstSubmitQcDate":"2012-10-31","dispFirstPostDateStruct":{"date":"2012-11-02","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-11-18","lastUpdatePostDateStruct":{"date":"2014-11-21","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Orexigen Therapeutics, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.","detailedDescription":"Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of 2 doses of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with uncomplicated obesity and in those with overweight/obesity and hypertension and/or dyslipidemia."},"conditionsModule":{"conditions":["Obesity","Overweight"],"keywords":["Obesity","Antiobesity agents","Antiobesity drugs","Overweight drug therapy","Obese drug therapy","Weight loss drug effects","Bupropion administration and dosage","Naltrexone administration and dosage","Double blind method","Combination drug therapy","Delayed action preparations"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1742,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"NB16","type":"EXPERIMENTAL","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy","interventionNames":["Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day","Behavioral: Ancillary therapy"]},{"label":"NB32","type":"EXPERIMENTAL","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy","interventionNames":["Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day","Behavioral: Ancillary therapy"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo with ancillary therapy","interventionNames":["Drug: Placebo","Behavioral: Ancillary therapy"]}],"interventions":[{"type":"DRUG","name":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day","armGroupLabels":["NB16"],"otherNames":["NB16"]},{"type":"DRUG","name":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day","armGroupLabels":["NB32"],"otherNames":["NB32"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"]},{"type":"BEHAVIORAL","name":"Ancillary therapy","description":"Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling","armGroupLabels":["NB16","NB32","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Co-primary: Body Weight- Mean Percent Change","timeFrame":"Baseline, 56 weeks"},{"measure":"Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease","timeFrame":"Baseline, 56 weeks"}],"secondaryOutcomes":[{"measure":"Body Weight- Proportion of Subjects With ≥10% Decrease","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Waist Circumference","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting HDL Cholesterol Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting Triglycerides Levels, Using Log-transformed Data","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in IWQOL-Lite Total Scores","description":"IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting Insulin Levels, Using Log-transformed Data","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting Blood Glucose Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in HOMA-IR Levels, Using Log-transformed Data","description":"HOMA-IR= Homeostasis Model Assessment-Insulin Resistance","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire","description":"Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting LDL Cholesterol Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Systolic Blood Pressure","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Diastolic Blood Pressure","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in IDS-SR Total Scores","description":"IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Food Craving Inventory Sweets Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Food Craving Inventory Carbohydrates Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","timeFrame":"Baseline, 56 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male subjects, 18 to 65 years of age;\n* Have BMI ≥30 and ≤45kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45kg/m² for subjects with obesity and controlled hypertension and/or dyslipidemia;\n* Normotensive (systolic ≤140 mm Hg; diastolic ≤90 mm Hg). Anti-hypertensive medications are allowed with the exception of alpha-adrenergic blockers and clonidine; medical regimen must be stable for at least 6 weeks prior to randomization;\n* Medications for treatment of dyslipidemia are allowed as long as medical regimen has been stable for at least 6 weeks prior to randomization;\n* Free of opioid medication for 7 days prior to randomization;\n* No clinically significant abnormality of serum albumin, blood urea nitrogen, creatinine, bilirubin, sodium, potassium, chloride, calcium or phosphorus;\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x upper limit of normal range (ULN);\n* No clinically significant abnormality of hematocrit, white blood cell (WBC) count, white cell differential, or platelets;\n* Fasting glucose \\< 126 mg/dL on no hypoglycemic agents, fasting triglycerides \\<400 mg/dL;\n* No clinically significant abnormality on urinalysis;\n* TSH within normal limits or normal T3, if TSH is below normal limits;\n* Negative serum pregnancy test in women of child-bearing potential;\n* Negative urine drug screen;\n* IDS-SR scores \\< 2 on items 5 (sadness), 6 (irritability), 7 (anxiety/tension) and 18 (suicidality), and IDS-SR total score \\< 30;\n* Women of child bearing potential had to be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug;\n* Able to comply with all required study procedures and schedule;\n* Able to speak and read English;\n* Willing and able to give written informed consent.\n\nExclusion Criteria:\n\n* Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome);\n* Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, Class III or IV congestive heart failure; myocardial infarction, history of angina pectoris, claudication, or acute limb ischemia within the previous 6 months; lifetime history of stroke);\n* History of malignancy within the previous 5 years with exception of non-melanoma skin cancer or surgically cured cervical cancer;\n* A lifetime history of serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, or anorexia nervosa;\n* Current serious psychiatric illness including severe personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt, current active suicidal ideation, or recent hospitalization due to psychiatric illness;\n* A response to bipolar disorder questions indicating the presence of bipolar disorder;\n* In need of medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months prior to randomization;\n* History of drug or alcohol abuse or dependence (with the exception of nicotine dependence) within 1 year prior to study initiation;\n* Type 1 or Type 2 diabetes mellitus;\n* Screening ECG with a corrected QT interval by the method of Bazett (QTcB) \\>450 msec (men) and \\> 470 millisecond (msec) (women) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities;\n* Excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant agents or agents for the treatment of Attention Deficit Disorder) with the exception of low dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over-the-counter dietary supplements or herbs with psychoactive, appetite or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; cholestyramine, cholestypol, Depo Provera®; smoking cessation agents; use of opioid or opioid-like medications, including analgesics and antitussives;\n* History of surgical or device (e.g., gastric banding) intervention for obesity;\n* History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures);\n* History of treatment with bupropion or naltrexone within the preceding 12 months;\n* History of hypersensitivity or intolerance to bupropion or naltrexone;\n* Initiation or discontinuation of tobacco products including inhaled tobacco (such as cigarettes, cigars, pipes, etc), chewing tobacco or snuff in the 3 months prior to randomization or planned during study participation. Use of nicotine replacement products (nicotine gum, patch) during study participation was not allowed;\n* Use of drugs, herbs, or dietary supplements believed to significantly affect body weight or participation in a weight loss management program within one month prior to randomization;\n* Loss or gain of more than 4.0 kilograms within 3 months prior to randomization;\n* Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug;\n* Planned surgical procedure that can impact the conduct of the study;\n* Use of investigational drug, device or procedure within the previous 30 days;\n* Participation in any previous clinical trial sponsored by Orexigen Therapeutics;\n* Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study;\n* Investigators, study personnel, sponsor representatives and their immediate families.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Radiant Research","city":"Birmingham","state":"Alabama","zip":"35209","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"SelfCenter, PC","city":"Fairhope","state":"Alabama","zip":"36532","country":"United States","geoPoint":{"lat":30.52297,"lon":-87.90333}},{"facility":"Radiant Research, Phoenix Southeast","city":"Chandler","state":"Arizona","zip":"85225","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Advanced Clinical Research Institute","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Advance Clinical Research Institute","city":"Orange","state":"California","zip":"92869","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Scripps Clinic Del Mar","city":"San Diego","state":"California","zip":"92130","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"VA San Diego Healthcare System","city":"San Diego","state":"California","zip":"92161","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Miami Research Associates","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"University Clinical Research","city":"Pembroke Pines","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Georgia Clinical Research","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"CSRA Partners in Health, Inc","city":"Augusta","state":"Georgia","zip":"30909","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"East-West Medical Research Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Radiant Research","city":"Chicago","state":"Illinois","zip":"60610","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Welborn Clinic","city":"Evansville","state":"Indiana","zip":"47713","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Radiant Research Kansas City","city":"Overland Park","state":"Kansas","zip":"66202","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Central Kentucky Research Associates, Inc.","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Pennington Biomedical Research Center","city":"Baton Rouge","state":"Louisiana","zip":"70808","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Medical Research Institute","city":"Slidell","state":"Louisiana","zip":"70458","country":"United States","geoPoint":{"lat":30.27519,"lon":-89.78117}},{"facility":"Health Trends Research, LLC","city":"Baltimore","state":"Maryland","zip":"21209","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"FutureCare Studies","city":"Springfield","state":"Massachusetts","zip":"01103","country":"United States","geoPoint":{"lat":42.10148,"lon":-72.58981}},{"facility":"Center for Nutrition and Metabolic Disorders","city":"Reno","state":"Nevada","zip":"89557","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Center for Nutrition and Preventive Medicine","city":"Charlotte","state":"North Carolina","zip":"28211","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Wake Research Associates, LLC","city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Rapid Medical Research, Inc.","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Central Ohio Nutrition Center, Inc.","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Lynn Health Science Institute","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Summit Research Network (Oregon), Inc.","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Internal Medicine Associates of Cordova","city":"Cordova","state":"Tennessee","zip":"38018","country":"United States","geoPoint":{"lat":35.15565,"lon":-89.7762}},{"facility":"Jackson Clinic, PA","city":"Jackson","state":"Tennessee","zip":"38305","country":"United States","geoPoint":{"lat":35.61452,"lon":-88.81395}},{"facility":"Covance Clinical Research Unit Austin","city":"Austin","state":"Texas","zip":"78752","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Radiant Research","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Baylor Endocrine Center","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Radiant Research","city":"San Antonio","state":"Texas","zip":"78217","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Oakwell Clinical Research","city":"San Antonio","state":"Texas","zip":"78218","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]},"referencesModule":{"references":[{"pmid":"20673995","type":"RESULT","citation":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"FG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"FG002","title":"Placebo","description":"Placebo"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"578"},{"groupId":"FG001","numSubjects":"583"},{"groupId":"FG002","numSubjects":"581"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"284"},{"groupId":"FG001","numSubjects":"296"},{"groupId":"FG002","numSubjects":"290"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"294"},{"groupId":"FG001","numSubjects":"287"},{"groupId":"FG002","numSubjects":"291"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"122"},{"groupId":"FG001","numSubjects":"112"},{"groupId":"FG002","numSubjects":"56"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"76"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"66"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"90"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"40"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Drug noncompliance, moved, other","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"29"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized subjects","groups":[{"id":"BG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"BG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"BG002","title":"Placebo","description":"Placebo"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"578"},{"groupId":"BG001","value":"583"},{"groupId":"BG002","value":"581"},{"groupId":"BG003","value":"1742"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44.35","spread":"11.25"},{"groupId":"BG001","value":"44.41","spread":"11.14"},{"groupId":"BG002","value":"43.66","spread":"11.14"},{"groupId":"BG003","value":"44.14","spread":"11.17"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"490"},{"groupId":"BG001","value":"496"},{"groupId":"BG002","value":"496"},{"groupId":"BG003","value":"1482"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"85"},{"groupId":"BG003","value":"260"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"48"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"14"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"15"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"110"},{"groupId":"BG003","value":"338"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"427"},{"groupId":"BG001","value":"440"},{"groupId":"BG002","value":"440"},{"groupId":"BG003","value":"1307"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"20"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"99.49","spread":"14.76"},{"groupId":"BG001","value":"99.70","spread":"15.88"},{"groupId":"BG002","value":"99.45","spread":"14.31"},{"groupId":"BG003","value":"99.55","spread":"14.99"}]}]}]},{"title":"BMI","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.22","spread":"4.28"},{"groupId":"BG001","value":"36.10","spread":"4.35"},{"groupId":"BG002","value":"36.18","spread":"4.00"},{"groupId":"BG003","value":"36.17","spread":"4.21"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Co-primary: Body Weight- Mean Percent Change","populationDescription":"Modified ITT (Full Analysis Set): Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of body weight","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"471"},{"groupId":"OG002","value":"511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.00","spread":"0.31"},{"groupId":"OG001","value":"-6.14","spread":"0.31"},{"groupId":"OG002","value":"-1.33","spread":"0.30"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-3.67","ciPctValue":"95","ciLowerLimit":"-4.50","ciUpperLimit":"-2.85"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-4.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.63","ciUpperLimit":"-3.99"}]},{"type":"PRIMARY","title":"Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"471"},{"groupId":"OG002","value":"511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.49","lowerLimit":"35.08","upperLimit":"43.91"},{"groupId":"OG001","value":"47.98","lowerLimit":"43.47","upperLimit":"52.49"},{"groupId":"OG002","value":"16.44","lowerLimit":"13.22","upperLimit":"19.65"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.42","ciPctValue":"95","ciLowerLimit":"2.52","ciUpperLimit":"4.63"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"4.86","ciPctValue":"95","ciLowerLimit":"3.60","ciUpperLimit":"6.57"}]},{"type":"SECONDARY","title":"Body Weight- Proportion of Subjects With ≥10% Decrease","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"471"},{"groupId":"OG002","value":"511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.17","lowerLimit":"16.55","upperLimit":"23.79"},{"groupId":"OG001","value":"24.63","lowerLimit":"20.74","upperLimit":"28.52"},{"groupId":"OG002","value":"7.44","lowerLimit":"5.16","upperLimit":"9.71"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.14","ciUpperLimit":"4.81"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"4.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.82","ciUpperLimit":"6.23"}]},{"type":"SECONDARY","title":"Change in Waist Circumference","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"cm","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"348"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.04","spread":"0.43"},{"groupId":"OG001","value":"-6.24","spread":"0.42"},{"groupId":"OG002","value":"-2.46","spread":"0.43"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-2.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.74","ciUpperLimit":"-1.43"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-3.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.93","ciUpperLimit":"-2.64"}]},{"type":"SECONDARY","title":"Change in Fasting HDL Cholesterol Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"359"},{"groupId":"OG002","value":"345"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.36","spread":"0.47"},{"groupId":"OG001","value":"3.42","spread":"0.45"},{"groupId":"OG002","value":"-0.06","spread":"0.47"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"3.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.17","ciUpperLimit":"4.66"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"3.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.26","ciUpperLimit":"4.70"}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides Levels, Using Log-transformed Data","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"359"},{"groupId":"OG002","value":"345"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.96","lowerLimit":"-11.35","upperLimit":"-4.44"},{"groupId":"OG001","value":"-12.69","lowerLimit":"-15.79","upperLimit":"-9.47"},{"groupId":"OG002","value":"-3.08","lowerLimit":"-6.62","upperLimit":"0.60"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"=0.046","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-4.88","ciNumSides":"TWO_SIDED"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-9.61","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change in IWQOL-Lite Total Scores","description":"IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"422"},{"groupId":"OG001","value":"417"},{"groupId":"OG002","value":"468"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.68","spread":"0.54"},{"groupId":"OG001","value":"12.69","spread":"0.54"},{"groupId":"OG002","value":"8.55","spread":"0.51"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"3.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.72","ciUpperLimit":"4.54"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"4.14","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.73","ciUpperLimit":"5.56"}]},{"type":"SECONDARY","title":"Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"},{"groupId":"OG001","value":"353"},{"groupId":"OG002","value":"340"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.02","lowerLimit":"-34.09","upperLimit":"-21.39"},{"groupId":"OG001","value":"-28.98","lowerLimit":"-34.79","upperLimit":"-22.65"},{"groupId":"OG002","value":"-16.66","lowerLimit":"-23.68","upperLimit":"-9.00"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"=0.016","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-11.36","ciNumSides":"TWO_SIDED"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"=0.008","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-12.32","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change in Fasting Insulin Levels, Using Log-transformed Data","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"344"},{"groupId":"OG002","value":"326"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.84","lowerLimit":"-17.28","upperLimit":"-6.05"},{"groupId":"OG001","value":"-17.14","lowerLimit":"-21.96","upperLimit":"-12.02"},{"groupId":"OG002","value":"-4.57","lowerLimit":"-10.35","upperLimit":"1.58"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"=0.063","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-7.27","ciNumSides":"TWO_SIDED"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-12.57","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change in Fasting Blood Glucose Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"},{"groupId":"OG001","value":"361"},{"groupId":"OG002","value":"348"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.39","spread":"0.57"},{"groupId":"OG001","value":"-3.24","spread":"0.55"},{"groupId":"OG002","value":"-1.30","spread":"0.56"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.60","ciUpperLimit":"0.42"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"=0.010","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-1.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.42","ciUpperLimit":"-0.46"}]},{"type":"SECONDARY","title":"Change in HOMA-IR Levels, Using Log-transformed Data","description":"HOMA-IR= Homeostasis Model Assessment-Insulin Resistance","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"305"},{"groupId":"OG001","value":"341"},{"groupId":"OG002","value":"325"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.33","lowerLimit":"-20.13","upperLimit":"-8.10"},{"groupId":"OG001","value":"-20.19","lowerLimit":"-25.26","upperLimit":"-14.78"},{"groupId":"OG002","value":"-5.90","lowerLimit":"-12.11","upperLimit":"0.74"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-8.43","ciNumSides":"TWO_SIDED"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-14.29","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire","description":"Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"},{"groupId":"OG002","value":"453"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.49","spread":"1.10"},{"groupId":"OG001","value":"-14.52","spread":"1.09"},{"groupId":"OG002","value":"-8.68","spread":"1.04"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-3.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.68","ciUpperLimit":"-0.94"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-5.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.71","ciUpperLimit":"-2.98"}]},{"type":"SECONDARY","title":"Change in Fasting LDL Cholesterol Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"332"},{"groupId":"OG001","value":"358"},{"groupId":"OG002","value":"345"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.67","spread":"1.21"},{"groupId":"OG001","value":"-4.41","spread":"1.17"},{"groupId":"OG002","value":"-3.28","spread":"1.20"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-0.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.62","ciUpperLimit":"2.84"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.484","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.29","ciUpperLimit":"2.04"}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mm Hg","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"471"},{"groupId":"OG002","value":"511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.40"},{"groupId":"OG001","value":"-0.11","spread":"0.41"},{"groupId":"OG002","value":"-1.94","spread":"0.39"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"2.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.16","ciUpperLimit":"3.30"},{"groupIds":["OG001","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"1.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"2.90"}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mm Hg","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"471"},{"groupId":"OG002","value":"511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.29"},{"groupId":"OG001","value":"0.04","spread":"0.29"},{"groupId":"OG002","value":"-0.86","spread":"0.28"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.19","ciUpperLimit":"1.73"},{"groupIds":["OG001","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.13","ciUpperLimit":"1.67"}]},{"type":"SECONDARY","title":"Change in IDS-SR Total Scores","description":"IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"470"},{"groupId":"OG002","value":"511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.21"},{"groupId":"OG001","value":"-0.27","spread":"0.21"},{"groupId":"OG002","value":"-0.72","spread":"0.20"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.19","ciUpperLimit":"1.28"},{"groupIds":["OG001","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.09","ciUpperLimit":"1.00"}]},{"type":"SECONDARY","title":"Change in Food Craving Inventory Sweets Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"423"},{"groupId":"OG001","value":"418"},{"groupId":"OG002","value":"470"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"0.21"},{"groupId":"OG001","value":"-2.62","spread":"0.21"},{"groupId":"OG002","value":"-2.77","spread":"0.20"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.14","ciUpperLimit":"1.23"},{"groupIds":["OG001","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.40","ciUpperLimit":"0.69"}]},{"type":"SECONDARY","title":"Change in Food Craving Inventory Carbohydrates Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day"},{"id":"OG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day"},{"id":"OG002","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"423"},{"groupId":"OG001","value":"418"},{"groupId":"OG002","value":"469"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.85","spread":"0.20"},{"groupId":"OG001","value":"-2.11","spread":"0.20"},{"groupId":"OG002","value":"-1.84","spread":"0.19"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-0.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.53","ciUpperLimit":"0.53"},{"groupIds":["OG001","OG002"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-0.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.80","ciUpperLimit":"0.27"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline, 56 weeks","description":"The safety analysis set includes all randomized subjects who took study drug and were assessed by investigator after their first dose, whether or not they discontinue the study. Treatment-emergent adverse events were defined as events that started or worsened in the double-blind treatment phase after the first dose and before 7 days post last dose.","eventGroups":[{"id":"EG000","title":"NB16","description":"Naltrexone SR 16 mg/Bupropion SR 360 mg /day","seriousNumAffected":9,"seriousNumAtRisk":569,"otherNumAffected":345,"otherNumAtRisk":569},{"id":"EG001","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg /day","seriousNumAffected":9,"seriousNumAtRisk":573,"otherNumAffected":365,"otherNumAtRisk":573},{"id":"EG002","title":"Placebo","description":"Placebo","seriousNumAffected":8,"seriousNumAtRisk":569,"otherNumAffected":230,"otherNumAtRisk":569}],"seriousEvents":[{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Hepatitis cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Whiplash injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Breast cancer in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Cervical myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":573},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":569}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":569},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":573},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":569}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":99,"numAffected":90,"numAtRisk":569},{"groupId":"EG001","numEvents":98,"numAffected":90,"numAtRisk":573},{"groupId":"EG002","numEvents":36,"numAffected":32,"numAtRisk":569}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":38,"numAffected":31,"numAtRisk":569},{"groupId":"EG001","numEvents":28,"numAffected":26,"numAtRisk":573},{"groupId":"EG002","numEvents":33,"numAffected":28,"numAtRisk":569}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":44,"numAffected":42,"numAtRisk":569},{"groupId":"EG001","numEvents":44,"numAffected":43,"numAtRisk":573},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":569}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":182,"numAffected":155,"numAtRisk":569},{"groupId":"EG001","numEvents":197,"numAffected":171,"numAtRisk":573},{"groupId":"EG002","numEvents":32,"numAffected":30,"numAtRisk":569}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":51,"numAffected":36,"numAtRisk":569},{"groupId":"EG001","numEvents":63,"numAffected":56,"numAtRisk":573},{"groupId":"EG002","numEvents":14,"numAffected":14,"numAtRisk":569}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":40,"numAffected":32,"numAtRisk":569},{"groupId":"EG001","numEvents":33,"numAffected":29,"numAtRisk":573},{"groupId":"EG002","numEvents":33,"numAffected":31,"numAtRisk":569}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":39,"numAffected":34,"numAtRisk":569},{"groupId":"EG001","numEvents":34,"numAffected":30,"numAtRisk":573},{"groupId":"EG002","numEvents":39,"numAffected":34,"numAtRisk":569}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":62,"numAffected":49,"numAtRisk":569},{"groupId":"EG001","numEvents":77,"numAffected":57,"numAtRisk":573},{"groupId":"EG002","numEvents":83,"numAffected":64,"numAtRisk":569}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":52,"numAffected":44,"numAtRisk":569},{"groupId":"EG001","numEvents":65,"numAffected":54,"numAtRisk":573},{"groupId":"EG002","numEvents":17,"numAffected":15,"numAtRisk":569}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":107,"numAffected":91,"numAtRisk":569},{"groupId":"EG001","numEvents":91,"numAffected":79,"numAtRisk":573},{"groupId":"EG002","numEvents":58,"numAffected":53,"numAtRisk":569}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":38,"numAffected":36,"numAtRisk":569},{"groupId":"EG001","numEvents":44,"numAffected":43,"numAtRisk":573},{"groupId":"EG002","numEvents":30,"numAffected":29,"numAtRisk":569}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":569},{"groupId":"EG001","numEvents":33,"numAffected":30,"numAtRisk":573},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":569}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection."},"pointOfContact":{"title":"Senior Vice President, Head of Global Development","organization":"Orexigen Therapeutics, Inc.","email":"MedInfo@Orexigen.com","phone":"(858) 875-8600"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":true}